Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Oleclumab or Monalizumab in Stage III NSCLC (PACIFIC-9)
NCT05221840Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2022
- Primary completion
- Jan 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 3 trial of oleclumab, monalizumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Feb 2022; status: active, not recruiting.
02
Drugs
oleclumabmonalizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05221840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05221840.